Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)

Journal of Infection

Volumn 69, Issue 3, 2014, Pages 266-277

  Sader, Helio S ^a   Farrell, David J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Ceftolozane tazobactam; ESBL; Pseudomonas aeruginosa; Urinary tract infections

Indexed keywords

AMIKACIN; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BROTH DILUTION; CONCENTRATION RESPONSE; ESCHERICHIA COLI; EUROPE; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PSEUDOMONAS AERUGINOSA; SERRATIA; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CITROBACTER; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTER; ENZYMOLOGY; GRAM NEGATIVE AEROBIC RODS AND COCCI; HUMAN; KLEBSIELLA OXYTOCA; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CITROBACTER; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ESCHERICHIA COLI; EUROPE; GRAM-NEGATIVE AEROBIC BACTERIA; HUMANS; INTRAABDOMINAL INFECTIONS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84922401795     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.04.004     Document Type: Article

References (19)

1. Bulik C.C., Christensen H., Nicolau D.P. Invitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 2010, 54:557-559.
2. Farrell D.J., Flamm R.K., Sader H.S., Jones R.N. Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013, 57:6305-6310.
3. Sader H.S., Rhomberg P.R., Farrell D.J., Jones R.N. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011, 55:2390-2394.
4. Craig W.A., Andes D.R. Invivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013, 57:1577-1582.
5. Vanscoy B., Mendes R.E., McCauley J., Bhavnani S.M., Bulik C.C., Okusanya O.O., et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 2013, 57:5924-5930.
6. Snydman D.R., McDermott L.A., Jacobus N.V. Activity of ceftolozane/tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2013, 58:1218-1223.
7. Clinical and Laboratory Standards Institute M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. 9th ed.
8. Clinical and Laboratory Standards Institute M100-S23 Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA.
9. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 2013, Available at:, [accessed 02.01.13]. http://www.eucast.org/clinical_breakpoints/.
10. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
11. Mazuski J.E., Solomkin J.S. Intra-abdominal infections. Surg Clin North Am 2009, 89:421-437.
12. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:133-164.
13. Lane D.R., Takhar S.S. Diagnosis and management of urinary tract infection and pyelonephritis. Emerg Med Clin North Am 2011, 29:539-552.
14. Wagenlehner F.M., Cek M., Naber K.G., Kiyota H., Bjerklund-Johansen T.E. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 2012, 30:59-67.
15. Briongos-Figuero L.S., Gomez-Traveso T., Bachiller-Luque P., Dominguez-Gil Gonzalez M., Gomez-Nieto A., Palacios-Martin T., et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 2012, 66:891-896.
16. Park S.Y., Kang C.I., Joo E.J., Ha Y.E., Wi Y.M., Chung D.R., et al. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012, 18:518-524.
17. Morata L., Cobos-Trigueros N., Martinez J.A., Soriano A., Almela M., Marco F., et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012, 56:4833-4837.
18. Peralta G., Sanchez M.B., Garrido J.C., De Benito I., Cano M.E., Martinez-Martinez L., et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007, 60:855-863.
19. Tygacil Tygacil® package insert 2012, Available at:, [accessed January 2013]. http://www.tygacil.com.